在接受Belantamab Mafodotin的患者中治疗眼部毒性的管理
Rebecca Lu1, Ashley Morphey1, Felicia Diaz1
1From The University of Texas MD Anderson Cancer Center, Houston, Texas.
Journal of the advanced practitioner in oncology
|June 14, 2023
概括
贝兰他马布 (Belantamab mafodotin) 为复发性或耐火性多发性髓瘤提供了一种新的治疗方法. 这种抗体-药物合物显示了31%的响应率,但需要仔细管理副作用,特别是眼部毒性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤的治疗选择是有限的,特别是对于那些对蛋白酶体抑制剂,免疫调节剂和抗CD38单克隆抗体等标准疗法不耐药的患者.
- 耐火性多发性骨髓瘤患者的中位生存期为5.8至13个月,这突显了迫切需要新的治疗策略.
研究的目的:
- 审查Belantamab mafodotin的疗效和安全数据,这是一种用于多发性骨髓瘤的新型抗体-药物联合体.
- 讨论治疗反应,毒性概况 (包括眼部毒性) 和贝兰他马布玛福多丁的管理策略.
主要方法:
- 对复发性/耐药性多发性骨髓瘤中贝兰他的临床试验数据和营销后监测的审查.
- 分析应答率,无进展生存率和不良事件概况,重点关注眼部毒性.
主要成果:
- 贝兰他马布 (Belantamab mafodotin) 在重量预先治疗的患者中,作为单一药物的整体响应率为31%.
- 无进展生存时间的中位数为2.9个月.
- 眼部毒性是需要特殊管理的显著不良事件.
结论:
- 贝兰他马布 (Belantamab mafodotin) 是治疗复发性/耐药性多发性骨髓瘤的宝贵补充,特别是对于已经耗尽其他选择的患者.
- 仔细监测和管理眼部毒性对于最佳的患者治疗结果至关重要.
相关概念视频
Anticholinesterase Agents: Poisoning and Treatment
926
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
926
Open Angle Glaucoma: Treatment
491
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
491


